e-learning
resources
ERJ
2017
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Exhaled breath to screen for malignant pleural mesothelioma: a validation study
Kevin Lamote, Matthijs Vynck, Olivier Thas, Joris Van Cleemput, Kristiaan Nackaerts, Jan P. van Meerbeeck
Source:
Eur Respir J, 50 (6) 1700919; 10.1183/13993003.00919-2017
Journal Issue:
December
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Kevin Lamote, Matthijs Vynck, Olivier Thas, Joris Van Cleemput, Kristiaan Nackaerts, Jan P. van Meerbeeck. Exhaled breath to screen for malignant pleural mesothelioma: a validation study. Eur Respir J, 50 (6) 1700919; 10.1183/13993003.00919-2017
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
Related content which might interest you:
Exhaled breath analysis allows exclusive screening for malignant pleural mesothelioma.
Source: International Congress 2017 – Mesothelioma and malignant pleural disease
Year: 2017
Chemical characterization of exhaled breath to discriminate patients with malignant pleural mesothelioma from subjects with similar professional asbestos exposure
Source: Annual Congress 2010 - Clinical diagnosis and management of malignant pleural effusions
Year: 2010
LATE-BREAKING ABSTRACT: An electronic nose distinguishes the exhaled breath of patients with pleural malignant mesothelioma from subjects with professional asbestos exposure
Source: Annual Congress 2009 - Diagnosis and management of pleural effusions and mesothelioma: improving old techniques and new tools
Year: 2009
Early detection of lung cancer through analysis of VOC biomarkers in exhaled breath: The LuCID study.
Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies
Year: 2017
Inflammatory markers in the exhaled breath condensate from patients with pulmonary sarcoidosis: comparison with BALF
Source: Eur Respir J 2006; 28: Suppl. 50, 353s
Year: 2006
Dermcidin identification from exhaled air for lung cancer diagnosis
Source: Eur Respir J 2010; 35: 1182-1185
Year: 2010
Breath analysis allows to predict treatment response in malignant pleural mesothelioma patients.
Source: Virtual Congress 2021 – Novel insights into the diagnosis, mechanism and treatment of malignant pleural disease
Year: 2021
3p microsatellite evaluation in NSCLC exhaled breath condensate: validation study
Source: Annual Congress 2007 - Novel genetic markers in pathology
Year: 2007
Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?
Source: Eur Respir Rev, 27 (147) 170098; 10.1183/16000617.0098-2017
Year: 2018
Exhaled breath analysis by use of eNose technology: a novel diagnostic tool for interstitial lung disease
Source: Eur Respir J, 57 (1) 2002042; 10.1183/13993003.02042-2020
Year: 2021
Exhaled biomarkers in lung cancer
Source: Eur Respir J 2009; 34: 261-275
Year: 2009
Protein markers in the exhaled breath condensate of lung carcinoma patients
Source: Annual Congress 2012 - Exhaled biomarkers in airway diseases
Year: 2012
Volatile organic compounds as an early diagnostic tool for malignant pleural mesothelioma
Source: International Congress 2014 – Diagnosis and treatment of pleural mesothelioma
Year: 2014
Exhaled breath molecular profiling by electronic nose in non-pulmonary malignancies
Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment
Year: 2009
Exhaled breath condensate - a new tool for assessment of idiopathic pulmonary fibrosis?
Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia
Year: 2018
Differential diagnosis between newly diagnosed asthma and COPD using exhaled breath condensate metabolomics: a pilot study
Source: Eur Respir J, 51 (3) 1701825; 10.1183/13993003.01825-2017
Year: 2018
Exhaled breath analysis using eNose technology in patients with sarcoidosis
Source: Virtual Congress 2020 – Sarcoidosis: from genetics to epidemiology
Year: 2020
Is the analysis of torbamycin in exhaled breath condensate a diagnostic tool to monitor pulmonary drug deposition?
Source: Eur Respir J 2004; 24: Suppl. 48, 386s
Year: 2004
Exhaled breath condensate biomarkers in COPD
Source: Eur Respir J 2008; 32: 472-486
Year: 2008
A breath test for malignant mesothelioma using an electronic nose
Source: Eur Respir J 2012; 40: 448-454
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept